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Abstract 
Background: Sulfadoxine–pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for 
programmes in the Democratic Republic of Congo (DRC). However, SP efficacy is threatened by drug resistance, that 
is conferred by mutations in the dhfr and dhps genes. The World Health Organization has specified that intermittent 
preventive treatment for infants (IPTi) with SP should be implemented only if the prevalence of the dhps K540E muta-
tion is under 50%. There are limited current data on the prevalence of resistance-conferring mutations available from 
Eastern DRC. The current study aimed to address this knowledge gap.
Methods: Dried blood-spot samples were collected from clinically suspected malaria patients [outpatient depart-
ment (OPD)] and pregnant women attending antenatal care (ANC) in four sites in North and South Kivu, DRC. Quan-
titative PCR (qPCR) was performed on samples from individuals with positive and with negative rapid diagnostic test 
(RDT) results. Dhps K450E and A581G and dhfr I164L were assessed by nested PCR followed by allele-specific primer 
extension and detection by multiplex bead-based assays.
Results: Across populations, Plasmodium falciparum parasite prevalence was 47.9% (1160/2421) by RDT and 71.7 
(1763/2421) by qPCR. Median parasite density measured by qPCR in RDT-negative qPCR-positive samples was very 
low with a median of 2.3 parasites/µL (IQR 0.5–25.2). Resistance genotyping was successfully performed in RDT-pos-
itive samples and RDT-negative/qPCR-positive samples with success rates of 86.2% (937/1086) and 55.5% (361/651), 
respectively. The presence of dhps K540E was high across sites (50.3–87.9%), with strong evidence for differences 
between sites (p < 0.001). Dhps A581G mutants were less prevalent (12.7–47.2%). The dhfr I164L mutation was found 
in one sample.
Conclusions: The prevalence of the SP resistance marker dhps K540E exceeds 50% in all four study sites in North and 
South Kivu, DRC. K540E mutations regularly co-occurred with mutations in dhps A581G but not with the dhfr I164L 
mutation. The current results do not support implementation of IPTi with SP in the study area.
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permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
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Background
Despite a decline in cases and deaths over the past 
20 years, malaria forms a major health problem in Africa. 
In the Democratic Republic of Congo (DRC) cases of 
malaria are rising, and the death toll is increasing [1]. In 
2017 in DRC there was an estimated number of 25 mil-
lion (15.7–36.8) cases of malaria and an estimated 46,800 
(36,200–57,300) deaths. The majority of malaria cases in 
DRC are caused by Plasmodium falciparum, although 
Plasmodium ovale [2], Plasmodium malariae, and Plas-
modium vivax are present among symptomatic cases [3]. 
Médecins sans Frontières (MSF) has been working in 
DRC since 1991. The Operational Centre Amsterdam of 
MSF (MSF–OCA) has several projects in Eastern DRC, 
most notably in North and South Kivu. Both provinces 
are the scene of chronic and at times intense conflict, 
leading to frequent internal displacement, outbreaks of 
disease, sexual violence, malnutrition, and a collapse of 
healthcare services. MSF supports several large hospitals 
and health centres and has adopted a strategy of Inte-
grated Community Case Management (ICCM). Within 
the ICCM programme, community members are trained 
to diagnose and treat malaria, diarrhoea and pneumo-
nia in children under 5 years of age. MSF and the Min-
istry of Health distribute insecticide-treated bed nets in 
the community as well as targeted distribution to preg-
nant women, severe malaria patients and other specific 
groups. Additional interventions are implemented where 
supportive evidence warrants it, aiming to reduce the 
burden of malaria. These interventions include chemo-
prevention strategies that are delivered without the need 
for testing. Sulfadoxine–pyrimethamine (SP) is a corner-
stone of malaria chemoprophylaxis across the African 
continent. Intermittent preventive treatment of malaria 
in pregnancy (IPTp) and intermittent preventive therapy 
for infants (IPTi) use SP alone, while seasonal malaria 
chemoprophylaxis (SMC) combines SP with amodi-
aquine. The efficacy of SP for these interventions is influ-
enced by drug resistance levels in parasite populations [4] 
and the drug resistance levels are influenced by the use of 
SP in target populations [5, 6].
The genetic basis of SP resistance is well understood, 
and consequently molecular surveillance of resistance 
mutations underpins current policy on SP use in Africa. 
SP resistance occurs via the accumulation of mutations in 
the dihydrofolate reductase (dhfr) gene and in the dihy-
dropteroate synthase (dhps) gene and these progressively 
reduce susceptibility to pyrimethamine and sulfadoxine, 
respectively. Infections harbouring triple mutant dhfr, 
i.e., a combination of N51I, C59R and S108N muta-
tions, are common throughout Africa. When this triple 
mutation in dhfr is combined with double-mutant dhps 
(A437G and K540E) the risk of SP treatment failure is up 
to 75% [7, 8]. A ‘sextuple mutant’ genotype in which these 
five key mutations in dhfr and dhps gene are accompa-
nied by dhps A581G is increasingly reported [9].
The World Health Organization (WHO) has specified 
that IPTi-SP should only be implemented in areas where 
the prevalence of the dhps K540E mutation (a proxy 
measure for the presence of all 5 key mutations) is under 
50% [10]. Molecular surveillance reports up to 2016 have 
recorded prevalence of K540E exceeding the 50% thresh-
old in 12 countries: most in East Africa (Sudan, Somalia, 
the Republic of the Congo, Tanzania, Malawi, Kenya, 
DRC, Mozambique, Ethiopia, Rwanda, Uganda, Zambia) 
[9], with relevant within-country variation. In the case of 
IPTp, SP continues to provide protection in pregnancy 
in all these areas except within restricted geographic 
areas where the dhps 581G is also present at high preva-
lence [4, 11–14]. One such area is confined to southwest 
Uganda, Rwanda and bordering areas of Eastern DRC. 
A study in 2013–2014 to survey small numbers of sam-
ples from all 25 districts of DRC found that prevalence 
of the sextuple mutant genotype is concentrated in North 
and South Kivu (Fig. 1), which are the districts bordering 
southwestern Uganda and Rwanda.
There are indications that the range and prevalence of 
the sextuple genotype is increasing [9]. This study aimed 
to update molecular surveillance data from North and 
South Kivu with more substantial sample sizes and exam-
ine the geographic heterogeneity in prevalence of 540E 
and 581G in order to determine if IPTi could be a pre-
ventive strategy used in MSF mission sites within these 
provinces of Eastern DRC.
Methods
Study area, subjects and sample collection
From August to September 2017, samples were collected 
in the context of MSF projects in two provinces: North 
Kivu and South Kivu. Each province provided samples 
from two study sites. The aim was to obtain a minimum 
of 250 samples with confirmed P. falciparum infection 
per study site from either pregnant women attending 
ANC or individuals attending the clinic with suspected 
malaria.
The sample size was based on the assumption of 50% 
prevalence of dhps K540E and the ability to estimate this 
expected proportion with 5% precision for each site. The 
Keywords: Malaria, DRC, Sulfadoxine–pyrimethamine (SP), Chemoprophylaxis, dhps, dhfr, K540E, A581G, I164L, IPTi
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study received ethical approval from the London School 
of Hygiene & Tropical Medicine (#11976), the Eth-
ics Review Board of MSF (#1708) and the Commission 
Institutionnelle d’Ethique of the Catholic University of 
Bukavu (UCB/ClE/NC/005B/2017). Informed consent 
was obtained from all participants or their carers prior 
to participation. Young adolescents received informa-
tion appropriate for their age before they were asked for 
consent.
Study participants were passively recruited at MSF 
clinics from pregnant women presenting for ANC and 
from patients presenting with signs/symptoms of malaria 
(axillary temperature ≥ 37.5  °C or history of fever). 
Malaria HRP2-test rapid diagnostic tests (RDTs) (SD 
BIOLINE Malaria Ag P.f, 05FK50; Gyeonggi-do, Repub-
lic of Korea) were performed to detect presence of P. 
falciparum antigen. Two blood spots were collected on 
filter papers  (Whatman® 903 Protein Saver Card; Maid-
stone, UK), air-dried, stored individually in zip-lock bags 
with desiccant at room temperature, and kept away from 
humidity, excessive heat and light. All dried blood spots 
(DBS) samples, whether RDT positive or negative, were 
shipped at ambient temperature to Radboud University 
Medical Centre, The Netherlands, for further processing.
Laboratory procedures
DNA was extracted from two 3-mm DBS punches using 
Chelex® 100 chelatin resin, according to the manufactur-
er’s recommendations, and using a filter (WHA77002808 
ALDRICH  Whatman®  UNIFILTER® plates) to avoid 
Chelex in the final DNA sample. DNA from both RDT 
positive and negative samples was tested using a qPCR 
assay targeting the P. falciparum-specific 18S gene [15]. 
This assay was originally optimized for use on whole 
blood samples (and not filter paper samples). For the 
current project, parasite density was quantified using 
in  vitro trendline material on filter paper  (Whatman® 
903 Protein Saver Card; Maidstone, UK) to have the same 
conditions for test samples and trendlines. For all qPCR 
positive samples, nested PCR amplification was done for 
dhps; for a sub-set of samples where dhps amplification 
was successful, dhfr was also amplified (n = 387). Prim-
ers were based on previous publications [16, 17] and are 
presented in Table 1. PCR conditions were 94 °C × 3 min, 
followed by 40 rounds of 94 °C × 1 min → 51 °C × 2 min 
→ 72  °C × 1 min, and a final round of 72  °C for 10 min. 
Samples were evaluated by gel electrophoresis prior to 
further analysis.
dhps K450E and A581G and dhfr I164L were assessed 
by nested PCR followed by allele specific primer exten-
sion (ASPE) and detection on a Luminex instrument 
 (MAGPIX®; Luminex Corp) with xPONENT® 4.2 
software. Briefly, amplified DNA was incubated with 
ExoSAPit for 30  min at 37  °C, followed by 15  min at 
80  °C. Samples were then assembled with the ASPE 
master mix [250  nM each of ASPE probes and 200  µM 
Biotin-14-dCTP (Invitrogen, UK)] using primers from 
Table  1 and incubated 30 cycles (30  s 90  °C, 1  min 
53.5  °C, 2  min 72  °C). Utilizing different TAGs on dif-
ferent ASPE primers, multiple magnetic bead sets could 
be hybridized to the ASPE reactions. For each reac-
tion, 1  μL of each bead set was used. After two washes 
with Tm buffer (0.2  M NaCl, 0.1  M Tris, 0.08% Tri-
tonX-100, pH 8), Tm buffer + 0.1% BSA + 2.5  μg/mL 
0 
0 - 0.1 
0.1 - 0.5 
0.5 - 1 
dhfr triple dhps 540 dhps 581 
Fig. 1 The prevalence of SP resistance markers. The prevalence of SP resistance markers in each of the 25 districts of the DRC 2013–2014 (redrawn 
from [25]). Administrative districts are shaded according to the prevalence of mutations. a The ‘dhfr triple’ containing N51I,C59R and S108N. b The 
dhps K540E. c The dhps A581G. SP sulphadoxine–pyrimethamine, dhfr dihydrofolate reductase, dhps dihydropteroate synthase
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Streptavidin-R-phycoerythrin (SAPE) was added to each 
sample. Samples were analysed at 37 °C on the Luminex 
analyser according to manufacturer’s instructions.
Statistical analysis
Statistical analyses were performed in STATA version 
15.0 (StataCorp; College Station, TX, USA). Data were 
typically presented per site and separately for sample 
donors recruited at clinics with suspected malaria (sus-
pected clinical cases) or pregnant women attending ante-
natal care (ANC participants). Age was categorized in 5 
categories (< 2 years, 2–4 years, 5–9 years, 10–14 years, 
≥ 15  years). Parasite density estimates were compared 
between RDT-positive and -negative individuals by non-
parametric Wilcoxon rank-sum test; median values with 
25th and 75th percentile (IQR) were presented. Parasite 
prevalence estimates were given for suspected clinical 
cases and ANC participants separately, adjusting 95% CI 
for the cluster-design of data collection using the survey 
(svy) command in STATA. Genotyping results were pre-
sented per site and separately for suspected clinical cases 
and ANC participants.
Results
RDT and qPCR results were available for a total of 2421 
individuals from the four study sites; data were unavail-
able for 83 additional participants because of missing 
blood spot samples (n = 8), errors in identification codes 
(n = 3) and laboratory errors/assay failures (n = 72). The 
majority of participants with successfully analysed sam-
ples were collected at clinics from suspected clinical 
malaria cases (78.8%, 1907/2421), the remainder com-
ing from ANC participants (Table 2). Across study sites, 
parasite prevalence by RDT was higher in suspected 
malaria cases (45.4%, 95% CI 31.7–59.9) compared to 
ANC participants (23.2; 95% CI 6.8–55.6%) (p = 0.026), 
taking into account a study site as primary sampling unit. 
Similarly, parasite prevalence by qPCR was higher in 
suspected malaria cases (78.0%, 95% CI 72.1–82.9) com-
pared to ANC participants (48.4; 95% CI 25.9–71.6%) 
(p = 0.029). Individuals who were RDT-positive were sig-
nificantly more likely to be qPCR-positive compared to 
RDT-negative individuals (OR 13.8, 95% CI 3.49–54.4, 
p = 0.009). Nevertheless, 47.8–67.4% of RDT-negative 
suspected clinical cases and 25.0–52.0% of RDT-negative 
ANC participants were found to be qPCR-positive in the 
four study sites. The estimated median parasite density 
by qPCR in RDT-positive individuals was 13,608  para-
sites/µL (IQR 384–108,600) compared to 2.3  parasites/
µL (IQR 0.5–25.2) in RDT-negative individuals (Fig.  2; 
p < 0.001).
Amplification of the dhps gene was successful for 86.2% 
(937/1086) of RDT-positive samples and 55.5% (361/651) 
of RDT-negative/qPCR-positive samples. All dhps posi-
tive samples were genotyped for dhps K540E and A581G 
and categorized as having a pure or mixed genotype for 
Table 1 Primer sequences
Listed are primer sequences used in qPCR to confirm P. falciparum infection and quantify parasite density (Pf18S), nested PCR for amplifying Dhps and Dhfr for ASPE 
reactions for hybridisation with different alleles. Sequence highlighted in italic is the Luminex tag sequence
qPCR quantitative polymerase chain reaction, Dhps dihydropteroate synthase; Dhfr dihydrofolate reductase, ASPE Allele Specific Primer Extension
Gene Primer/probe Sequence
Pf18S 18S forward 5′GTA ATT GGA ATG ATA GGA ATT TAC AAGGT 3′ 
Pf18S 18S reverse 5′TCA ACT ACG AAC GTT TTA ACT GCA AC 3′
Pf18S 18S probe 6FAM-AAC AAT TGG AGG GCAAG–MGBNFQ
Dhps Outer forward 5′ GAT TCT TTT TCA GAT GGA GG 3′
Dhps Outer reverse 5′ TTC CTC ATG TAA TTC ATC TGA 3′
Dhps Inner forward 5′ AAC CTA AAC GTG CTG TTC AA 3′
Dhps Inner reverse 5′ AAT TGT GTG ATT TGT CCA CAA 3′
Dhfr Outer forward 5′ TGA TGG AAC AAG TCTGC 3′
Dhfr Outer reverse 5′ ACT TTG TTT ATT TCC ATT CA 3′
Dhfr Inner forward 5′ TGT GCA TGT TGT AAG GTT GA 3′
Dhfr Inner reverse 5′ GAT ACT CAT TTT CAT TTA TTT CTG GA 3′
Dhps 540 K 5′ ATT AAA CAA CTC TTA ACT ACA CAA GGA AAT CCA CAT ACA ATG GATA 3′
Dhps 540 E 5′ CTT TCT TAA TAC ATT ACA ACA TAC GAA ATC CAC ATA CAA TGG ATG 3′
Dhps 581 A 5′ CAT AAA TCT TCT CAT TCT AAC AAA TTG ATA TTG GAT TAG GAT TTGC 3′
Dhps 581 G 5′ CAA ACA AAC ATT CAA ATA TCA ATC TTG ATA TTG GAT TAG GAT TTGG 3′
Dhfr 164 I 5′ CAT AAA TCT TCT CAT TCT AAC AAA GAA ATT AAA TTA CTA TAA ATG TTT TATTA 3′
Dhfr 164 L 5′ CAA ACA AAC ATT CAA ATA TCA ATC GAA ATT AAA TTA CTA TAA ATG TTT TATTT 3′
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each locus (Table 3, Additional file 1: Table S1). The pres-
ence of dhps K540E, either as pure mutant or as mixed 
mutant/wild-type infections, exceeded 50% in all study 
sites, with strong evidence for differences between sites 
(p < 0.001) (Fig. 3). dhps A581G mutants were less prev-
alent than dhps K540E; only in Mweso approximately 
half of all infections carried the 581G as pure mutant 
or mixed wild-type/mutant. Again, there was strong 
evidence for differences in the prevalence of the dhps 
A581G mutation between sites (p < 0.001). The dhps 
A581G mutation almost exclusively occurred in the pres-
ence of the dhps K540E mutation: 100.0% (143/143) of all 
dhps A581G pure mutant and 96.2 (128/133) of all mixed 
wildtype/mutant infections had concurrent mutations in 
dhps K540E.
The dhfr gene was successfully amplified in 94.9% 
(333/351) of randomly selected samples (Baraka: n = 78; 
Kimbi: n = 91; Walikale: n = 96; Mweso: n = 68). Among 
these samples, the dhfr I164L mutation was found in only 
one sample (0.3%, 1/333). The sample was collected from 
an RDT-confirmed clinical malaria case from Walikale 
and was wild type for dhps K540E and A581G.
Discussion
High numbers of malaria cases continue to pose an 
intense burden to DRC and to the individuals affected. 
Due to conflict and unrest in the country, there is lim-
ited current information available on parasite resistance 
to anti-malarial drugs. This knowledge gap hinders the 
informed use of anti-malarial interventions. The current 
study aimed to provide estimates of molecular mark-
ers conferring SP resistance in four settings in an area of 
chronic conflict in Eastern DRC.
Parasite prevalence among suspected malaria cases 
was uniformly high in the study settings. When sensitive 
qPCR was used to detect P. falciparum parasites, parasite 
prevalence was 70–80% among suspected malaria cases 
and 32–65% among women attending ANC visits. These 
findings confirm the high malaria burden in this part of 
DRC [18]. The higher prevalence of parasites by qPCR 
compared to RDT corroborates an increasing body of 
literature on low-density infections that are present in 
Table 2 Characteristics of study participants
Clinic samples from individuals attending the clinic with suspected clinical malaria, ANC samples from individuals attending antenatal care, RDT rapid diagnostic test 
SD Bioline, qPCR quantitative polymerase chain reaction, n absolute number, N total sample size per location
Baraka Kimbi Walikale Mweso
Suspected clinical malaria 500 415 662 330
Antenatal visits 169 151 73 121
Age, % (n)
 < 2 years 19.9 (133) 21.8 (123) 14.3 (105) 12.0 (54)
 2–4 years 20.9 (140) 30.3 (171) 17.1 (125) 13.1 (59)
 5–9 years 17.2 (115) 2.1 (12) 17.9 (131) 13.3 (60)
 10–14 years 6.4 (43) 1.6 (9) 14.6 (107) 11.3 (51)
 ≥ 15 years 35.6 (238) 44.2 (249) 36.2 (265) 50.3 (227)
Parasite prevalence RDT, % (n/N)
 Clinic 47.2 (236/500) 50.6 (210/415) 64.1 (424/662) 51.8 (171/330)
 ANC 9.5 (16/169) 32.5 (49/151) 50.7 (37/73) 14.1 (17/121)
Parasite prevalence qPCR, % (n/N)
 Clinic 81.2 (406/500) 74.9 (311/415) 79.8 (528/662) 73.3 (242/330)
 ANC 41.4 (70/169) 64.9 (98/151) 57.5 (42/73) 32.2 (39/121)
Fig. 2 Parasite density estimated by 18S quantitative PCR in RDT 
negative and positive individuals. qPCR quantitative polymerase chain 
reaction, RDT rapid diagnostic test; SD Bioline. The box plots present 
median and interquartile range densities; whiskers indicate the 10th 
and 90th percentile
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Table 3 The prevalence of mutations in Dhps 540 and Dhps 581 in the different study sites
N total sample size per location, n absolute number, Dhps dihydropteroate synthase
Baraka Kimbi Walikale Mweso
Clinic Clinic Clinic Clinic
N 302 352 365 174
Dhps 540, % (n)
 Wildtype 29.8 (90) 49.7 (175) 21.1 (77) 12.1 (21)
 Pure mutant 56.6 (171) 25.0 (88) 61.9 (226) 75.3 (131)
 Mixed 13.6 (41) 25.3 (89) 17.0 (62) 12.6 (22)
N 314 360 377 178
Dhps 581, % (n)
 Wildtype 78.0 (245) 87.2 (314) 78.8 (297) 52.8 (94)
 Pure mutant 12.1 (38) 4.4 (16) 10.1 (38) 30.3 (54)
 Mixed 9.9 (31) 8.3 (30) 11.1 (42) 16.9 (30)
mutant
wild-type
mutant + wild-type
dhps 540 dhps 581
540K+581A (wildtype+wildtype)
540E+581A (mutant+wildtype)
540E+581G (mutant+mutant)
dhps 540+581
a b c
Fig. 3 Prevalence of dhps K540E and 581G mutations at the 4 MSF sites. The number of infections carrying pure mutant, mixed (mutant + wildtype) 
or pure wildtype infections are shown for dhps K540E (a), A581G (b) m and the haplotypes of dhps 540 and 581 at each site (c). dhps 
dihydropteroate synthase
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all age groups and across all endemicities in Africa and 
elsewhere [19, 20]. Parasite densities among RDT-neg-
ative qPCR-positive individuals were very low on aver-
age, below the threshold density typically detected by 
microscopy or RDT [19]. Whilst this suggests adequate 
performance of RDTs in the study settings in sympto-
matic cases, deletions in histidine-rich protein (HRP2), 
as described in DRC by Parr et al. [21] will be examined 
in the current dataset in future studies. It is currently 
unclear whether parasite densities below the threshold 
for detection by RDT contribute to acute clinical dis-
ease in semi-immune individuals, although low-density 
infections have been associated with haemolysis, inflam-
mation, co-infection with invasive bacterial disease, 
cognitive impairment [22], and ongoing transmission 
of parasites to mosquitoes [23]. At present, it may be 
assumed that RDT-negative individuals presenting with 
suspected malaria had fever due to causes other than P. 
falciparum infection [24].
A high level of the dhps K540E mutation was observed 
in this region and this is consistent with studies that 
reviewed and mapped all publicly available data on 540E 
in Africa [9, 25, 26]. At all sites, the prevalence of dhps 
K540E mutant exceeds 50%, the threshold level defined 
by WHO to determine whether or not to introduce IPTi 
[27]. The highest prevalence of 540E was in the eastern 
sites (Mweso and Baraka), closest to the border with 
southwest Uganda and western Rwanda, a region pre-
viously identified as a hotspot with a high level of SP 
resistance [25, 26]. This is consistent with the east–west 
gradient in the spatial distribution of the dhps mutations 
across DRC observed by Aydemir et al. [28] and summa-
rized in Fig. 1. Okell et al. showed that resistance patterns 
are similar for sites up to 300  km apart [9] and Mweso 
is < 300 km from resistant hotspots in southwest Uganda 
[29, 30].
This study is consistent with a sequential build-up of 
resistance markers for SP. The A581G mutation almost 
exclusively occurred in the presence of K540E mutations 
[31]. The prevalence of I164L mutation on the dhfr gene 
was still very low, detected in only one of 333 samples. 
Future monitoring is needed to examine if the prevalence 
of this mutation is increasing and will have implications 
for SP efficacy. A relevant limitation of the current study 
is that samples were collected on one time-point only and 
solely collected at clinical facilities in suspected malaria 
cases and women attending ANC (routine screening of 
all pregnant women, including asymptomatically infected 
individuals). Some of the suspected malaria cases with 
measured fever and qPCR-or RDT-detected infections 
may have had fever due to causes other than malaria 
[24] and may have inappropriately received the diagnosis 
of clinical malaria. Whilst this misclassification is of no 
concern for the current objectives, estimating the preva-
lence of resistance markers among health facility attend-
ees, it complicates a direct comparison of resistance in 
clinical versus asymptomatic infections.
The findings in this study are disappointing from a 
programmatic perspective. The study was initiated with 
the hope that IPTi could be introduced in the region to 
reduce morbidity and mortality. However, with resistance 
markers well above the threshold of 50% (for K540E) this 
cannot be supported. Although WHO still recommends 
IPTp with SP in areas with high level of resistance to SP, 
based on studies in Tanzania and Malawi [32], the cur-
rent findings of high prevalence of SP resistance among 
the target population suggest that the efficacy of IPTp 
in this setting should continue to be monitored [33] 
and alternative drugs such as dihydroartemisinin–pipe-
raquine, mefloquine or doxycycline may be worth con-
sidering [34–36].
The current findings highlight significant challenges for 
the use of SP for chemoprevention in this region in DRC. 
It is therefore of utmost importance that other inter-
ventions, including vector control and prompt access to 
diagnosis and treatment, are implemented to the high-
est attainable standards to reduce exposure and prevent 
severe disease.
Conclusion
In the study areas of intense malaria transmission in 
North and South Kivu, the prevalence of the SP resist-
ance marker dhps K540E was above 50% in all study sites. 
K540E mutations regularly coincided with mutations in 
dhps A581G but not with the dhfr I164L mutation. The 
current results do not support implementation of IPTi. 
Given the high morbidity and mortality from malaria in 
DRC, alternative approaches are needed for prevention 
and early treatment of malaria.
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